Asthma Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 or older, of any gender
- People with a confirmed diagnosis of severe eosinophilic asthma (a type of asthma involving high levels of certain immune cells), as defined by major respiratory medical guidelines, who are already being treated with high-dose inhaled steroids plus a long-acting bronchodilator
- People for whom a doctor has already prescribed benralizumab (a biologic asthma medication) based on standard prescribing and reimbursement criteria — the treatment decision must have been made before and separately from this study
- People who are able and willing to read and understand written instructions
- People who have signed a consent form showing they understand the study's purpose and procedures and agree to take part
- People who are willing to report on their asthma symptoms every 4 weeks and record their medication use weekly
Who may not be able to join:
- People currently taking part in another observational study that the trial investigators believe could affect this study's results, or who took part in a randomised clinical trial within the last 3 months
- People with a history of a severe allergic reaction (anaphylaxis) to any biologic medication
- People who have received any biologic therapy for asthma within the last 3 months
- People currently using any other biologic therapy for asthma at the same time
- People diagnosed with a parasitic worm (helminth) infection within the past 24 weeks that has not been successfully treated
- People with a lung condition other than asthma that, in the investigator's view, could affect how the study results are interpreted
- People with any ongoing or long-term condition that, in the investigator's view, could limit their ability to complete questionnaires or participate fully in the study
- People with a history of cancer within the last 5 years — with two exceptions: cervical carcinoma in situ where treatment is complete and the person has been in remission for at least 12 months, or certain minor skin cancers (basal cell carcinoma or superficial squamous cell skin cancer)
- People who are pregnant or breastfeeding (the investigator is required to ask about this)
- People with any other condition that, in the investigator's opinion, could put their safety at risk
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 1-877-240-9479
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in Asthma Control Test (ACT) total score in patients from baseline to week 12, 24 and 52 after first benralizumab dose; Proportion of responders at baseline, week 12, 24 and 52 after first benralizumab dose, using ACT; Change in daily doses of prescribed inhaled corticosteroids (ICS) intake from baseline to week 12, 24 and 52 after first benralizumab dose; Change in daily doses of patient-reported inhaled corticosteroids (ICS) intake from baseline to week 12, 24 and 52 after first benralizumab dose; Reduction (in percentage) in prescribed daily ICS dose intake from baseline to week 52 a...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.